BioMarin's Narrow Moat Supported by Rare Disease Therapies and Developing Pipeline
BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
Zacks.com on MSN8 小时
BioMarin Q4 Earnings & Sales Top Estimates, Stock Up on Upbeat '25 View
BioMarin Pharmaceutical BMRN reported fourth-quarter adjusted earnings per share of 92 cents, which beat the Zacks Consensus ...
Zacks Research Has Bullish Forecast for BMRN Q4 Earnings
Zacks Research boosted their Q4 2025 earnings per share (EPS) estimates for BioMarin Pharmaceutical in a research note issued on Monday, February 17th. Zacks Research analyst S. Ganoria now ...